MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

MDT

84.7

+0.83%↑

VEEV

231.57

+2.63%↑

A

107.51

+0.6%↑

WBA

10.91

-0.46%↓

CHE

575.22

+1.75%↑

Search

Lyell Immunopharma Inc

Closed

0.42 -2.33

Overview

Share price change

24h

Current

Min

0.41

Max

0.45

Key metrics

By Trading Economics

Income

-147M

-192M

Sales

-23K

11K

EPS

-0.172

Profit margin

-1,744,863.636

Employees

300

EBITDA

-12M

-58M

Recommendations

By TipRanks

Recommendations

Sell

12 Months Forecast

+122.22% upside

Dividends

By Dow Jones

Next Earnings

5 May 2025

Market Stats

By TradingEconomics

Market Cap

-87M

129M

Previous open

2.75

Previous close

0.42

Technical Score

By Trading Central

Confidence

Weak Bullish Evidence

Lyell Immunopharma Inc Chart

Past performance is not a reliable indicator of future results.

Related News

29 Apr 2025, 23:53 UTC

Hot Stocks

Stocks to Watch: Starbucks, Snap, Super Micro Computer, Seagate Technology

29 Apr 2025, 23:06 UTC

Earnings

Prudential PLC 1Q New Business Profit Increases by 12%

29 Apr 2025, 23:00 UTC

Earnings

America Movil's Posts Rise in 1Q Profit, Revenue

30 Apr 2025, 00:00 UTC

Top News

Buffett's 'Woodstock for Capitalists' Draws Admirers From Around the Globe -- WSJ

29 Apr 2025, 23:46 UTC

Market Talk

Nikkei May Rise as Fears About U.S. Tariffs Ebb -- Market Talk

29 Apr 2025, 23:43 UTC

Market Talk

Gold Consolidates; Signs of Easing in U.S. Tariffs' Impact May Weigh -- Market Talk

29 Apr 2025, 23:41 UTC

Earnings

China Minsheng Banking 1Q Net Interest Income CNY24.87B Vs. CNY24.26B>1988.HK

29 Apr 2025, 23:41 UTC

Earnings

China Minsheng Banking 1Q Operating Income CNY36.81B Vs. CNY34.27B>1988.HK

29 Apr 2025, 23:41 UTC

Earnings

China Minsheng Banking 1Q Net CNY12.74B Vs. Net CNY13.45B >1988.HK

29 Apr 2025, 23:24 UTC

Earnings

China Vanke 1Q Rev CNY37.99B Vs. CNY61.59B >000002.SZ

29 Apr 2025, 23:24 UTC

Earnings

China Vanke: Increase in Investment Losses Also Hurt Results >000002.SZ

29 Apr 2025, 23:24 UTC

Earnings

China Vanke 1Q Loss CNY6.25B Vs. Loss CNY361.97M >000002.SZ

29 Apr 2025, 23:24 UTC

Earnings

China Vanke: Singificant Decline in Property Sales Weighed on Results >000002.SZ

29 Apr 2025, 23:24 UTC

Earnings

China Vanke 1Q Loss Widened Significantly >000002.SZ

29 Apr 2025, 23:15 UTC

Top News

UPS to Cut 20,000 Jobs After Amazon Breakup -- 2nd Update

29 Apr 2025, 23:14 UTC

Earnings

China Eastern Airlines 1Q Loss CNY995.0M Vs. Loss CNY803.0M >0670.HK

29 Apr 2025, 23:14 UTC

Earnings

China Eastern Airlines: Increased Competition in the Aviation Market Hurt Results >0670.HK

29 Apr 2025, 23:14 UTC

Earnings

China Eastern Airlines 1Q Rev CNY33.41B Vs. CNY33.19B >0670.HK

29 Apr 2025, 23:14 UTC

Earnings

China Eastern Airlines 1Q Loss Widened >0670.HK

29 Apr 2025, 23:11 UTC

Earnings

China Southern Airlines Swung to Loss in 1Q>1055.HK

29 Apr 2025, 23:11 UTC

Earnings

China Southern Airlines 1Q Rev CNY43.41B Vs. CNY44.60B >1055.HK

29 Apr 2025, 23:11 UTC

Earnings

China Southern Airlines: Shift in Traveler Demographics, Competition From High-Speed Rail Networks Also Hurt Results >1055.HK

29 Apr 2025, 23:11 UTC

Earnings

China Southern Airlines 1Q Loss CNY747.0M Vs. Net CNY756.0M >1055.HK

29 Apr 2025, 23:11 UTC

Earnings

China Southern Airlines: CNY Depreciation, Global Supply Chain Constraints Among Factors Weighing on Results >1055.HK

29 Apr 2025, 23:07 UTC

Earnings

Air China 1Q Rev CNY40.02B Vs. CNY40.07B >0753.HK

29 Apr 2025, 23:07 UTC

Earnings

Air China 1Q Losses Widened>0753.HK

29 Apr 2025, 23:07 UTC

Earnings

Air China 1Q Loss CNY2.04B Vs. Loss CNY1.67B >0753.HK

29 Apr 2025, 23:02 UTC

Earnings

COSCO SHIPPING Energy Transportation: Weaker Earnings In International Oil Tanker Fleet Business Weighed on Results>1138.HK

29 Apr 2025, 23:02 UTC

Earnings

COSCO SHIPPING Energy Transportation 1Q Net CNY707.70M Vs. Net CNY1.24B >1138.HK

29 Apr 2025, 23:02 UTC

Earnings

COSCO SHIPPING Energy Transportation 1Q Rev CNY5.75B Vs. CNY5.84B >1138.HK

Peer Comparison

Price change

Lyell Immunopharma Inc Forecast

Price Target

By TipRanks

122.22% upside

12 Months Forecast

Average 1 USD  122.22%

High 1 USD

Low 1 USD

Based on 2 Wall Street analysts offering 12 month price targets forLyell Immunopharma Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Sell

2 ratings

0

Buy

1

Hold

1

Sell

Technical Score

By Trading Central

0.429 / 0.4588Support & Resistance

Short Term

Weak Bullish Evidence

Intermediate Term

Neutral Evidence

Long Term

No Evidence

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Lyell Immunopharma Inc

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic. It is also developing LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T cell product candidate that is in Phase 1 clinical trial for the treatment of various solid tumors; and LYL845, a novel epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate, which is in Phase 1 clinical trial targeting multiple solid tumor indications. In addition, the company's preclinical product candidates include LYL119, a ROR1 CAR T-cell product for the treatment of enhanced cytotoxicity; and second generation TIL product. Lyell Immunopharma, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.